Home »
NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. 201020_CMI (REF: 201009_PI) This medicine is subject to additional monitoring. This will allow quick identificationof new safety information. You can help by reporting any side effects you may get.You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems . Ravulizumab rch […]
BOSTON–(BUSINESS WIRE)– December 21, 2018 — Alexion Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvz), the first and only long-acting C5 complement inhibitor administered every eight weeks, for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH), a debilitating ultra-rare blood disorder characterized by complement-mediated destruction […]